| BRAVOS: Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study |
Mayes |
(NIH/NIAID) |
| A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Diffuse Cutaneous Systemic Sclerosis |
Mayes |
Mitsubishi Tanabe Pharma Development America, Inc. |
| A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Explore Efficacy of TEPEZZA in Patients with Diffuse Cutaneous Systemic Sclerosis |
Mayes |
Horizon Therapeutics U.S.A., Inc. |
| Classification of Axial Spondyloarthritis Inception Cohort (CLASSIC) |
Reveille |
Spondyloarthritis Research and Treatment Network (SPARTAN) |
| A Multicenter, Long-Term Extension Study of 104 Weeks, including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal – Retreatment Period, to Evaluate the Maintenance of treatment Effect of Ixekizumab in Patients with Axial Spondyloarthritis |
Reveille |
Lilly USA, LLC |
| Individualizing Anti-Inflammatory Medications for Adults with Axial Spondyloarthritis: A Series of N-of 1 Trials |
Hwang |
NIH |